After This Answer From ActBlue's CEO, Republicans Should've Expected This Wouldn't Go Well
The AP Amazingly Declares in Court It Does Not Need to Follow Its...
Ignore All of the World Cup Meltdowns; This German Road Trip Account Marveling...
Spencer Pratt Isn’t Laughing at Jimmy Kimmel’s 'Jokes'
Here's What Victor Davis Hanson Has to Say About Graham Platner's Victory in...
Nine Convicted in Ohio Drug Ring That Mixed Fentanyl Trafficking With $4.5M COVID-19...
Democrat Calls Republicans Fascists, Wishes He Could 'Run Over' Trump at Congressional Bas...
8 Indicted for Allegedly Threatening University of Michigan Leaders, Jewish Federation
Massachusetts Doctor Sentenced to Nearly 5 Years for Healthcare Fraud, Tax Evasion, Money...
CENTCOM Confirms U.S. Resumes Strikes on Iran After Helicopter Shot Down
Democrat Rep. Summer Lee Says Equity Policies Are Only a Threat to White...
Romanian Man Sentenced to 5 Years, Ordered to Pay $11M for Walmart Card-Skimming...
Republicans Add to Narrow House Majority With New Member
Here's How Much Oil Went Through the Strait of Hormuz Under a 'Secret...
Philadelphia Teachers Just Admitted the Real Reason Behind the Failure of the Public...
Tipsheet

Rep. Maloney: Republicans Would Reject Cancer Cure

Rep. Maloney: Republicans Would Reject Cancer Cure

On top of being terrorists and hostage takers, Democrat Rep. Carolyn Maloney apparently thinks Republicans hate cancer patients  because they wouldn't budge on tax hikes during the debt debate.

Advertisement

"If President Obama came in with a cure for cancer they would have turned that down, too," she said.

FLASHBACK: Rationing for cancer patients begins through ObamaCare.

A decision to rescind endorsement of the drug would reignite the highly charged debate over US health care reform and how much the state should spend on new and expensive treatments.

Avastin, the world’s best selling cancer drug, is primarily used to treat colon cancer and was approved by the US Food and Drug Administration in 2008 for use on women with breast cancer that has spread.

It costs $8,000 (£5,000) a month and is given to about 17,500 women in the US a year. The drug was initially approved after a study found that, by preventing blood flow to tumours, it extended the amount of time until the disease worsened by more than five months. However, two new studies have shown that the drug may not even extend life by an extra month.

The FDA advisory panel has now voted 12-1 to drop the endorsement for breast cancer treatment. The panel unusually cited "effectiveness" grounds for the decision. But it has been claimed that "cost effectiveness" was the real reason ahead of reforms in which the government will extend health insurance to the poorest.

 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos